Earnings Call · Q1 FY2026·2026-05-07

Q1 26EPS -44.90%·Rev n/aQ4 25EPS 0.00%·Rev n/aQ3 25EPS -56.00%·Rev n/aQ2 25EPS -38.89%·Rev n/a⚠ consensus missing

Definium Therapeutics, Inc. DFTX

Gita Jain — Head of Investor Relations

Robert Barrow — Chief Executive Officer

Daniel Karlin — Chief Medical Officer

Matthew Wiley — Chief Commercial Officer

Brandi L. Roberts — Chief Financial Officer

−5.0%1d on move date−5.8% vs SPY3d−8.8%5d−8.0%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more DFTX calls or request research access.

More DFTX calls Browse calls Request research access